Advertisement

New Drug Approvals for Sarcoma in the Last 5 Years

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kelly C.M.
        • Gutierrez Sainz L.
        • Chi P.
        The management of metastatic GIST: current standard and investigational therapeutics.
        J Hematol Oncol. 2021; 14: 2
        • Shetty N.
        • Sirohi B.
        • Shrikhande S.V.
        Molecular target therapy for gastrointestinal stromal tumors.
        Translational Gastrointest Cancer. 2015; 4: 207-218
        • Farag S.
        • Smith M.J.
        • Fotiadis N.
        • et al.
        Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates.
        Curr Treat Options Oncol. 2020; 21: 55
        • Nannini M.
        • Tarantino G.
        • Indio V.
        • et al.
        Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRalpha mutation in a metastatic GIST patient responding to imatinib.
        Sci Rep. 2019; 9: 2172
        • Mazzocca A.
        • Napolitano A.
        • Silletta M.
        • et al.
        New frontiers in the medical management of gastrointestinal stromal tumours.
        Ther Adv Med Oncol. 2019; 11 (1758835919841946)
        • Napolitano A.
        • Vincenzi B.
        Secondary KIT mutations: the GIST of drug resistance and sensitivity.
        Br J Cancer. 2019; 120: 577-578
        • Bauer S.
        • George S.
        • von Mehren M.
        • et al.
        Early and next-generation KIT/PDGFRA kinase inhibitors and the future of treatment for advanced gastrointestinal stromal tumor.
        Front Oncol. 2021; 11: 672500
        • Smith B.D.
        • Kaufman M.D.
        • Lu W.P.
        • et al.
        Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA Variants.
        Cancer Cell. 2019; 35: 738-751 e9
        • George S.
        • Heinrich M.
        • Chi P.
        • et al.
        Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens.
        Ann Oncol. 2018; 29: viii576-viii577
        • Blay J.-Y.
        • Serrano C.
        • Heinrich M.C.
        • et al.
        Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2020; 21: 923-934
        • Zalcberg J.R.
        Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
        Therap Adv Gastroenterol. 2021; 14 (17562848211008177)
        • George S.
        • Chi P.
        • Heinrich M.C.
        • et al.
        Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.
        Eur J Cancer. 2021; 155: 236-244
      1. News in Brief in Cancer Discovery: Testing Ripretinib against Sunitinib in GIST. Cancer Discov. 2022 Mar 1;12(3):591-592. doi: 10.1158/2159-8290.CD-NB2022-0004. PMID: 35086925.

      2. Evans EK., Gardino AK., Kim JL., et al.,. A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med. 2017 Nov 1;9(414):eaao1690. doi: 10.1126/scitranslmed.aao1690. PMID: 29093181.

        • Gebreyohannes Y.K.
        • Wozniak A.
        • Zhai M.E.
        • et al.
        Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors.
        Clin Cancer Res. 2019; 25: 609-618
        • Heinrich M.C.
        • Jones R.L.
        • von Mehren M.
        • et al.
        Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
        Lancet Oncol. 2020; 21: 935-946
        • Heinrich M.C.
        • Jones R.L.
        • von Mehren M.
        • et al.
        Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).
        J Clin Oncol. 2019; 37: 11022
        • George S.
        • Jones R.L.
        • Bauer S.
        • et al.
        Avapritinib in patients with advanced gastrointestinal stromal tumors following at least three prior lines of therapy.
        Oncologist. 2021; 26: e639-e649
      3. Heinrich M vMM, Jones RL. Avapritinib is highly active and well-tolerated in patients (pts) with advanced GIST driven by diverse variety of oncogenic mutations in KIT and PDGFRA. Presented at the Connective Tissue Oncology Society Annual meeting (CTOS), Nov 14-17th 2018, Rome, Italy

        • Ghadimi M.P.
        • Liu P.
        • Peng T.
        • et al.
        Pleomorphic liposarcoma: clinical observations and molecular variables.
        Cancer. 2011; 117: 5359-5369
        • Judson I.
        • Verweij J.
        • Gelderblom H.
        • et al.
        Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
        Lancet Oncol. 2014; 15: 415-423
        • Italiano A.
        • Toulmonde M.
        • Cioffi A.
        • et al.
        Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.
        Ann Oncol. 2012; 23: 1601-1607
        • Livingston J.A.
        • Bugano D.
        • Barbo A.
        • et al.
        Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard.
        Scientific Rep. 2017; 7: 11836
      4. Thirasastr P AB, Lin H, Roland C, Feig B, Keung E et al. Efficacy of Gemcitabine- Docetaxel in Dedifferentiated Liposarcoma. presented at the Connective Tissue Oncology Society (CTOS) Annual Virtual Meeting, Nov 16-19th 2021.

        • Maki R.G.
        • Wathen Jk
        • Fau-Patel S.R.
        • et al.
        Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
        J Clin Oncol. 2007; 25 (Electronic)): 1527-7755
        • Demetri G.D.
        • von Mehren M.
        • Jones R.L.
        • et al.
        Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial.
        J Clin Oncol. 2016; 34: 786-793
        • Swami U.
        • Chaudhary I.
        • Ghalib M.H.
        • et al.
        Eribulin -- a review of preclinical and clinical studies.
        Crit Rev Oncol Hematol. 2012; 81: 163-184
        • Schöffski P.
        • Ray-Coquard I.L.
        • Cioffi A.
        • et al.
        Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
        Lancet Oncol. 2011; 12: 1045-1052
        • Schöffski P.
        • Chawla S.
        • Maki R.G.
        • et al.
        Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
        Lancet. 2016; 387: 1629-1637
        • Demetri G.D.
        • Schöffski P.
        • Grignani G.
        • et al.
        Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III Study of Eribulin Versus Dacarbazine.
        J Clin Oncol. 2017; 35: 3433-3439
        • Osgood C.L.
        • Chuk M.K.
        • Theoret M.R.
        • et al.
        FDA approval summary: eribulin for patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
        Clin Cancer Res. 2017; 23 (Electronic)): 1557-3265
        • Kau T.R.
        • Way J.C.
        • Silver P.A.
        Nuclear transport and cancer: from mechanism to intervention.
        Nat Rev Cancer. 2004; 4: 106-117
        • Garg M.
        • Kanojia D.
        • Mayakonda A.
        • et al.
        Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.
        Oncotarget. 2017; 8: 7521-7532
      5. Gounder MRA, Somaiah N, et al. A phase 2/3, randomized, double blind, cross-over, study of selinexor versus placebo in advanced unresectable dedifferentiated liposarcoma. Presented at the Connective Tissue Oncology Society (CTOS) Annual Virtual Meeting, Nov 18-21st 2020. Abstract 20.

        • Abdul Razak A.R.
        • Mau-Soerensen M.
        • Gabrail N.Y.
        • et al.
        First-in-class, first-in-human phase i study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors.
        J Clin Oncol. 2016; 34: 4142-4150
        • Gounder M.
        • Abdul Razak A.R.
        • Gilligan A.M.
        • et al.
        Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
        Future Oncol. 2021; 17: 2923-2939
        • de Pinieux G.
        • Karanian M.
        • Le Loarer F.
        • et al.
        Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network.
        PLoS One. 1932; 2021 (Electronic)): 6203
        • Modena P.
        • Lualdi E.
        • Facchinetti F.
        • et al.
        SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas.
        Cancer Res. 2005; 65 (0008-5472 (Print)): 4012-4019
        • Chbani L.
        • Guillou L.
        • Terrier P.
        • et al.
        Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group.
        Am J Clin Pathol. 2009; 131: 222-227
        • Phelan M.L.
        • Sif S.
        • Narlikar G.J.
        • et al.
        Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits.
        Mol Cell. 1999; 3: 247-253
        • Wilson B.G.
        • Wang X.
        • Shen X.
        • et al.
        Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation.
        Cancer Cell. 2010; (Electronic)): 1878-3686
        • Blay J.Y.
        • Hindi N.
        • Bollard J.
        • et al.
        SELNET clinical practice guidelines for soft tissue sarcoma and GIST.
        Cancer Treat Rev. 2022; 102 (Electronic)): 102312
        • von Mehren M.
        • Kane J.M.
        • Bui M.M.
        • et al.
        NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021.
        J Natl Compr Canc Netw. 2020; 18: 1604-1612
        • Frezza A.M.
        • Jones R.L.
        • Lo Vullo S.
        • et al.
        Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
        JAMA Oncol. 2018; 4: e180219
        • Touati N.
        • Schoffski P.
        • Litiere S.
        • et al.
        European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.
        Clin Oncol (R Coll Radiol). 2018; 30: 448-454
        • Pink D.
        • Richter S.
        • Gerdes S.
        • et al.
        Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-institutional analysis.
        Oncology. 2014; 87: 95-103
        • Italiano A.
        • Soria J.C.
        • Toulmonde M.
        • et al.
        Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
        Lancet Oncol. 2018; 19: 649-659
        • Davis J.L.
        • Al-Ibraheemi A.
        • Rudzinski E.R.
        • et al.
        Mesenchymal neoplasms with NTRK and other kinase gene alterations.
        Histopathology. 2022; 80: 4-18
        • Drilon A.
        • Siena S.
        • Ou S.I.
        • et al.
        Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
        Cancer Discov. 2017; 7: 400-409
        • Laetsch T.W.
        • DuBois S.G.
        • Mascarenhas L.
        • et al.
        Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
        Lancet Oncol. 2018; 19: 705-714
        • Hong D.S.
        • DuBois S.G.
        • Kummar S.
        • et al.
        Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
        Lancet Oncol. 2020; 21: 531-540
        • Paz-Ares L.
        • Barlesi F.
        • Siena S.
        • et al.
        Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.
        ESMO Open. 2021; 6: 100113
        • Krebs M.G.
        • Blay J.Y.
        • Le Tourneau C.
        • et al.
        Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications.
        ESMO Open. 2021; 6 (2059-7029 (Electronic)): 100072
        • Desmoid Tumor Working G.
        The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients.
        Eur J Cancer. 2020; 127 (1879-0852(Electronic)): 96-107
        • Gounder M.M.
        • Mahoney M.R.
        • Van Tine B.A.
        • et al.
        Sorafenib for Advanced and Refractory Desmoid Tumors.
        N Engl J Med. 2018; 379: 2417-2428
        • Toulmonde M.
        • Pulido M.
        • Ray-Coquard I.
        • et al.
        Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.
        Lancet Oncol. 2019; 20: 1263-1272
        • Villalobos V.M.
        • Hall F.
        • Jimeno A.
        • et al.
        Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.
        Ann Surg Oncol. 2018; 25: 768-775
        • Palmerini E.
        • Staals E.L.
        • Maki R.G.
        • et al.
        Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors.
        Eur J Cancer. 2015; 51 (1879-0852 (Electronic)): 210-217
        • Mastboom M.J.L.
        • Palmerini E.
        • Verspoor F.G.M.
        • et al.
        Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study.
        Lancet Oncol. 2019; 20: 877-886
        • West R.B.
        • Rubin B.P.
        • Miller M.A.
        • et al.
        A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.
        Proc Natl Acad Sci U S A. 2006; 103: 690-695
        • Blay J.Y.
        • Sayadi H.
        • Thiesse P.
        • Thiesse P.
        • et al.
        Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).
        Ann Oncol. 2008; 19 (1569-8041 (Electronic)): 821-822
        • Cassier P.A.
        • Gelderblom H.
        • Stacchiotti S.
        • et al.
        Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.
        Cancer. 2012; 118 (1097-0142 (Electronic)): 1649-1655
        • Cassier P.A.
        • Italiano A.
        • Gomez-Roca C.A.
        • et al.
        CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
        Lancet Oncol. 2015; 16: 949-956
        • Gelderblom H.
        • Cropet C.
        • Chevreau C.
        • et al.
        Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial.
        Lancet Oncol. 2018; 19: 639-648
        • Tap W.D.
        • Wainberg Z.A.
        • Anthony S.P.
        • et al.
        Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
        N Engl J Med. 2015; 373: 428-437
        • Tap W.D.
        • Gelderblom H.
        • Palmerini E.
        • et al.
        Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
        Lancet. 2019; 394: 478-487
        • Brahmi M.
        • Cassier P.
        • Dufresne A.
        • et al.
        Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT).
        PLoS One. 2020; 15: e0233046
        • Doyle L.A.
        • AP
        • Hornick J.L.
        PEComa.
        in: WHO classification of tumors editorial board. Soft tissue and bone tumours. International Agency for Research on Cancer, Lyon (France)2020: 312-314
        • Folpe A.L.
        • Kwiatkowski D.J.
        Perivascular epithelioid cell neoplasms: pathology and pathogenesis.
        Hum Pathol. 2010; 41: 1-15
        • Stacchiotti S.
        • Frezza A.M.
        • Blay J.Y.
        • et al.
        Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities.
        Cancer. 2021; 127: 2934-2942
        • Kenerson H.
        • Folpe A.L.
        • Takayama T.K.
        • et al.
        Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms.
        Hum Pathol. 2007; 38: 1361-1371
        • Dufresne A.
        • Brahmi M.
        • Karanian M.
        • et al.
        Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours.
        Nat Rev Clin Oncol. 2018; 15 (1759-4782 (Electronic)): 443-458
        • Sanfilippo R.
        • Jones R.L.
        • Blay J.Y.
        • et al.
        Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).
        Clin Cancer Res. 2019; 25: 5295-5300
        • Wagner A.J.
        • Malinowska-Kolodziej I.
        • Morgan J.A.
        • et al.
        Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
        J Clin Oncol. 2010; 28: 835-840
        • Wagner A.J.
        • Ravi V.
        • Riedel R.F.
        • et al.
        nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors.
        J Clin Oncol. 2021; 39: 3660-3670
        • Kim Y.J.
        • Kim M.
        • Park H.K.
        • et al.
        Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology.
        Lab Invest. 2019; 99: 1309-1320
        • Marine J.C.
        • Lozano G.
        Mdm2-mediated ubiquitylation: p53 and beyond.
        Cell Death Differ. 2010; 17: 93-102
        • O'Leary B.
        • Finn R.S.
        • Turner N.C.
        Treating cancer with selective CDK4/6 inhibitors.
        Nat Rev Clin Oncol. 2016; 13: 417-430
        • Dickson M.A.
        • Tap W.D.
        • Keohan M.L.
        • et al.
        Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
        J Clin Oncol. 2013; 31: 2024-2028
        • Dickson M.A.
        • Schwartz G.K.
        • Keohan M.L.
        • et al.
        Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.
        JAMA Oncol. 2016; 2: 937-940
        • Dickson M.A.
        • Koff A.
        • D'Angelo S.P.
        • et al.
        Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.
        J Clin Oncol. 2019; 37: 11004
      6. von Mehren M., Kane JM., Bui MM., et al., NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. J Natl Compr Canc Netw. 2020 Dec 2;18(12):1604-1612. doi: 10.6004/jnccn.2020.0058. PMID: 33285515.

        • Gazendam A.M.
        • Popovic S.
        • Munir S.
        • et al.
        Synovial sarcoma: a clinical review.
        Curr Oncol. 2021; 28: 1909-1920
        • Svejstrup J.Q.
        Synovial sarcoma mechanisms: a series of unfortunate events.
        Cell. 2013; 153: 11-12
        • Hostein I.
        • Menard A.
        • Bui B.N.
        • et al.
        Molecular detection of the synovial sarcoma translocation t(X;18) by real-time polymerase chain reaction in paraffin-embedded material.
        Diagn Mol Pathol. 2002; 11: 16-21
        • Baranov E.
        • Black M.A.
        • Fletcher C.D.M.
        • et al.
        Nuclear expression of DDIT3 distinguishes high-grade myxoid liposarcoma from other round cell sarcomas.
        Mod Pathol. 2021; 34: 1367-1372
        • Tawbi H.A.
        • Burgess M.
        • Bolejack V.
        • et al.
        Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
        Lancet Oncol. 2017; 18: 1493-1501
        • Lai J.P.
        • Robbins P.F.
        • Raffeld M.
        • et al.
        NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
        Mod Pathol. 2012; 25: 854-858
        • Mitchell G.
        • Pollack S.M.
        • Wagner M.J.
        Targeting cancer testis antigens in synovial sarcoma.
        J Immunother Cancer. 2021; 9: e002072
        • Jungbluth A.A.
        • Antonescu C.R.
        • Busam K.J.
        • et al.
        Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7.
        Int J Cancer. 2001; 94: 252-256
        • Rohaan M.W.
        • Wilgenhof S.
        • Haanen J.
        Adoptive cellular therapies: the current landscape.
        Virchows Arch. 2019; 474: 449-461
        • Robbins P.F.
        • Kassim S.H.
        • Tran T.L.
        • et al.
        A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
        Clin Cancer Res. 2015; 21: 1019-1027
        • D'Angelo S.P.
        • Melchiori L.
        • Merchant M.S.
        • et al.
        Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 (c259)T Cells in Synovial Sarcoma.
        Cancer Discov. 2018; 8: 944-957
        • D'Angelo S.P.
        • Mahoney M.R.
        • Van Tine B.A.
        • et al.
        Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
        Lancet Oncol. 2018; 19: 416-426
        • Toulmonde M.
        • Penel N.
        • Adam J.
        • et al.
        Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
        JAMA Oncol. 2018; 4: 93-97
        • Groisberg R.
        • Hong D.S.
        • Behrang A.
        • et al.
        Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.
        J Immunother Cancer. 2017; 5: 100
        • Wilky B.A.
        • Trucco M.M.
        • Subhawong T.K.
        • et al.
        Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.
        Lancet Oncol. 2019; 20: 837-848
        • Somaiah N.
        • Conley A.P.
        • Lin H.Y.
        • et al.
        A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.
        J Clin Oncol. 2020; 38: 11509
        • Naqash A.R.
        • O'Sullivan Coyne G.H.
        • Moore N.
        • et al.
        Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).
        J Clin Oncol. 2021; 39: 11519